dc.contributor.author | Pishva, H | |
dc.contributor.author | Amini, M | |
dc.contributor.author | Eshraghian, MR | |
dc.contributor.author | Hosseini, S | |
dc.contributor.author | Mahboob, SA | |
dc.date.accessioned | 2018-08-26T08:53:04Z | |
dc.date.available | 2018-08-26T08:53:04Z | |
dc.date.issued | 2012 | |
dc.identifier.uri | http://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/53872 | |
dc.description.abstract | Background: Fatty acid binding protein 2 (FABP2) and peroxisome proliferator-activated receptor ? (PPAR?) are involved in cellular uptake and metabolism of fatty acids. Polymorphism of FABP2 and PPAR? may influence plasma levels of fatty acids in those who take supplemental eicosapentaenoic acid (EPA). The purpose of this study was to study the potential associations between the Ala54/Thr polymorphism in FABP2 protein and the Leu162/Val in exon 5 and G/C in intron 7 of PPAR? with plasma fatty acids composition after EPA supplementation.Methods: Twenty three FABP2 Ala54 and twenty three Thr54 carriers with hypertriglyceridemia were enrolled in this study. Participants took 2 g of pure EPA daily for 8 wks. Plasma fatty acids composition was determined and changes from the baseline were measured. Results: Although EPA supplementation increased the level of plasma EPA and ?-3 fatty acids in both carriers of FABP2 and PPAR? genes, these effects were more pronounced in Thr54 and Val162 carriers. EPA supplementation decreased the level of some n-6 fatty acids such as arachidonic acid.Conclusion: EPA consumption has more favorable effects on blood n-3 fatty acids and can change the level of plasma n-3 fatty acids, particularly EPA. Because the FABP2 Thr54 polymorphism appears to be prevalent in hypertriglyceridemic subjects, increasing EPA intake in these subjects could be an effective strategy for preventing cardiovascular diseases. Finally, diets and micronutrient recommendations should be individualized for high risk people. © 2012 Pishva et al.; licensee BioMed Central Ltd. | |
dc.language.iso | English | |
dc.relation.ispartof | Journal of Diabetes and Metabolic Disorders | |
dc.subject | 11 ecosenoic acid | |
dc.subject | 11, 14 ecosadienoic acid | |
dc.subject | 15 tetracosenoic acid | |
dc.subject | alanine | |
dc.subject | arachidic acid | |
dc.subject | arachidonic acid | |
dc.subject | behenic acid | |
dc.subject | dihomo gamma linolenic acid | |
dc.subject | fatty acid binding protein 2 | |
dc.subject | gamma linolenic acid | |
dc.subject | icosapentaenoic acid | |
dc.subject | leucine | |
dc.subject | linoleic acid | |
dc.subject | miristic acid | |
dc.subject | monounsaturated fatty acid | |
dc.subject | oleic acid | |
dc.subject | omega 3 fatty acid | |
dc.subject | omega 6 fatty acid | |
dc.subject | palmitic acid | |
dc.subject | peroxisome proliferator activated receptor alpha | |
dc.subject | polyunsaturated fatty acid | |
dc.subject | saturated fatty acid | |
dc.subject | stearic acid | |
dc.subject | threonine | |
dc.subject | unclassified drug | |
dc.subject | valine | |
dc.subject | icosapentaenoic acid | |
dc.subject | article | |
dc.subject | drug effect | |
dc.subject | exon | |
dc.subject | fatty acid blood level | |
dc.subject | genetic association | |
dc.subject | genetic polymorphism | |
dc.subject | genotype | |
dc.subject | human | |
dc.subject | hypertriglyceridemia | |
dc.subject | intron | |
dc.subject | lipid composition | |
dc.subject | plasma fatty acids composition | |
dc.subject | supplementation | |
dc.subject | treatment duration | |
dc.subject | amino acid substitution | |
dc.subject | Article | |
dc.subject | clinical article | |
dc.subject | controlled study | |
dc.subject | diet supplementation | |
dc.subject | drug mechanism | |
dc.subject | fatty acid blood level | |
dc.subject | genetic polymorphism | |
dc.subject | genetic variability | |
dc.subject | heterozygote | |
dc.subject | hypertriglyceridemia | |
dc.subject | treatment response | |
dc.title | Effects of EPA supplementation on plasma fatty acids composition in hypertriglyceridemic subjects with FABP2 and PPAR? genotypes | |
dc.type | Book Chapter | |
dc.citation.volume | 11 | |
dc.citation.issue | 1 | |
dc.citation.index | Scopus | |
dc.identifier.DOI | https://doi.org/10.1186/2251-6581-11-25 | |